129 related articles for article (PubMed ID: 38776787)
1. Estimation of passive gastrointestinal absorption of new dual DNA gyrase and topoisomerase IV inhibitors using PAMPA and biopartitioning micellar chromatography and quantitative structure-retention relationship analysis.
Dobričić V; Marodi M; Marković B; Tomašič T; Durcik M; Zidar N; Mašič LP; Ilaš J; Kikelj D; Čudina O
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jun; 1240():124158. PubMed ID: 38776787
[TBL] [Abstract][Full Text] [Related]
2. Biopartitioning micellar chromatography as a predictive tool for skin and corneal permeability of newly synthesized 17β-carboxamide steroids.
Dobričić V; Nikolic K; Vladimirov S; Čudina O
Eur J Pharm Sci; 2014 Jun; 56():105-12. PubMed ID: 24607748
[TBL] [Abstract][Full Text] [Related]
3. Application of biopartitioning micellar chromatography and QSRR modeling for prediction of gastrointestinal absorption and design of novel β-hydroxy-β-arylalkanoic acids.
Dobričić V; Savić J; Nikolic K; Vladimirov S; Vujić Z; Brborić J
Eur J Pharm Sci; 2017 Mar; 100():280-284. PubMed ID: 28126559
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D
J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
7. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
Tomašič T; Katsamakas S; Hodnik Ž; Ilaš J; Brvar M; Solmajer T; Montalvão S; Tammela P; Banjanac M; Ergović G; Anderluh M; Peterlin Mašič L; Kikelj D
J Med Chem; 2015 Jul; 58(14):5501-21. PubMed ID: 26098163
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J
Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
[TBL] [Abstract][Full Text] [Related]
11. Biopartitioning micellar chromatography under different conditions: Insight into the retention mechanism and the potential to model biological processes.
Tsopelas F; Danias P; Pappa A; Tsantili-Kakoulidou A
J Chromatogr A; 2020 Jun; 1621():461027. PubMed ID: 32276854
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors.
Axford LC; Agarwal PK; Anderson KH; Andrau LN; Atherall J; Barker S; Bennett JM; Blair M; Collins I; Czaplewski LG; Davies DT; Gannon CT; Kumar D; Lancett P; Logan A; Lunniss CJ; Mitchell DR; Offermann DA; Palmer JT; Palmer N; Pitt GR; Pommier S; Price D; Narasinga Rao B; Saxena R; Shukla T; Singh AK; Singh M; Srivastava A; Steele C; Stokes NR; Thomaides-Brears HB; Tyndall EM; Watson D; Haydon DJ
Bioorg Med Chem Lett; 2013 Dec; 23(24):6598-603. PubMed ID: 24239017
[TBL] [Abstract][Full Text] [Related]
13. Estimation of passive gastrointestinal absorption and membrane retention using PAMPA test, quantitative structure-permeability and quantitative structure-retention relationship analyses of ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid and 1,3-propanediamine-N,N'-di-2-(3-cyclohexyl)propanoic acid derivatives.
Tubić B; Dobričić V; Poljarević J; Savić A; Sabo T; Marković B
J Pharm Biomed Anal; 2020 May; 184():113213. PubMed ID: 32126457
[TBL] [Abstract][Full Text] [Related]
14. Design, green one-pot synthesis and molecular docking study of novel N,N-bis(cyanoacetyl)hydrazines and bis-coumarins as effective inhibitors of DNA gyrase and topoisomerase IV.
Metwally NH; Abdallah SO; Mohsen MMA
Bioorg Chem; 2020 Apr; 97():103672. PubMed ID: 32145481
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
16. Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy.
Perola E; Stamos D; Grillot AL; Ronkin S; Wang T; LeTiran A; Tang Q; Deininger DD; Liao Y; Tian SK; Drumm JE; Nicolau DP; Tessier PR; Mani N; Grossman TH; Charifson PS
Bioorg Med Chem Lett; 2014 May; 24(9):2177-81. PubMed ID: 24685546
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel 2-aminobenzothiazole derivatives as potential antimicrobial agents with dual DNA gyrase/topoisomerase IV inhibition.
Ismail MMF; Abdulwahab HG; Nossier ES; El Menofy NG; Abdelkhalek BA
Bioorg Chem; 2020 Jan; 94():103437. PubMed ID: 31812260
[TBL] [Abstract][Full Text] [Related]
18. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
19. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
[TBL] [Abstract][Full Text] [Related]
20. Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.
Fisher LM; Pan XS
Methods Mol Med; 2008; 142():11-23. PubMed ID: 18437302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
